古塞奇尤单抗治疗日本中重度斑块状银屑病的随机安慰剂对照剂量递增研究
该研究为双盲、安慰剂对照、单次皮下给药剂量递增研究,纳入日本中重度斑块状银屑病患者(体表面积≥10%且PASI≥12),按5:1随机接受古塞奇尤单抗或安慰剂。结果显示古塞奇尤单抗总体耐受良好,第16周观察到最大临床应答,药代动力学呈剂量比例增加。
要点
- 古塞奇尤单抗总体耐受良好,未报告死亡、严重不良事件或导致停药的不良事件。
- 第16周观察到最大临床应答,各剂量组PASI 75和PASI 90应答均有报告。
核心结论
- 古塞奇尤单抗在日本中重度斑块状银屑病患者中总体耐受良好,并表现出持续高水平的临床应答。
研究设计与样本
- 双盲、安慰剂对照、单次递增剂量、单中心研究,患者按5:1随机接受古塞奇尤单抗或安慰剂,随访24周。
- 纳入标准为体表面积受累≥10%且PASI≥12的日本中重度斑块状银屑病患者。
主要发现
- 至第24周,古塞奇尤单抗组55%(11/20)和安慰剂组50%(2/4)的患者经历至少1次不良事件。
- 未报告死亡、严重不良事件或导致治疗中断的不良事件。
- 第16周观察到最大临床应答:PASI 75应答在10 mg组为2/5、30 mg组为4/5、100 mg组为3/5、300 mg组为4/5。
- PASI 90应答在10 mg组为0/5、30 mg组为3/5、100 mg组为2/5、300 mg组为3/5。
临床怎么用
- 古塞奇尤单抗单次皮下给药在日本中重度斑块状银屑病患者中显示出可接受的 safety 特征和临床应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interleukin (IL)-23/IL-17 pathway is central in the pathogenesis of psoriasis. The favourable efficacy and safety of guselkumab, an IL-23-specific monoclonal antibody, has been demonstrated in global phase III studies of plaque psoriasis. OBJECTIVES: To evaluate the safety, efficacy and pharmacokinetics of single-dose subcutaneous guselkumab in Japanese patients with moderate-to-severe plaque psoriasis. METHODS: Patients with ≥ 10% of total body surface area involvement and a Psoriasis Area and Severity Index (PASI) ≥ 12 were randomized (5 : 1) to receive guselkumab or placebo in four cohorts of this double-blind, placebo-controlled, single ascending-dose, single-centre study. Safety, pharmacokinetics and clinical response were monitored at baseline and specific time points over a 24-week follow-up period. RESULTS: To week 24, 55% (11/20) of patients in the guselkumab group and 50% (2/4) in the placebo group experienced ≥1 adverse event (AE). No deaths, serious AEs or AEs leading to treatment discontinuation were reported. Maximum clinical response was seen at week 16 with PASI 75 (≥ 75% improvement from baseline PASI) response in two of five (10 mg), four of five (30 mg and 300 mg) and three of five (100 mg) patients; and PASI 90 (≥ 90% improvement from baseline PASI) in zero of five (10 mg), three of five (30 mg), two of five (100 mg) and three of five (300 mg) patients. Mean maximum serum concentration (Cmax ) and area under the curve from time zero to infinity values increased in a dose-proportional manner with a mean terminal half-life of 15·6-17·6 days and median time to reach Cmax of 4-6 days. CONCLUSIONS: Guselkumab was generally well-tolerated and exhibited sustained high levels of clinical response in Japanese patients with moderate-to-severe psoriasis.
引用
- Nemoto O, Hirose K, Shibata S, et al. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Br J Dermatol. 2018. PMID: 29222947. doi:10.1111/bjd.16236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。